O’Melveny & Myers LLP represented Dicerna Pharmaceuticals, Inc., an emerging pharmaceutical company developing RNA interference-based therapeutics against genetically defined targets in multiple disease areas, in a Series C preferred stock financing in which Dicerna raised US$60 million.

The O’Melveny team was led by Jennifer DePalma, Ruchun Ji, and Sam Zucker.



Related Posts:

Leave a Reply